213 related articles for article (PubMed ID: 1671296)
1. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain.
Akiyama T; Matsuda S; Namba Y; Saito T; Toyoshima K; Yamamoto T
Mol Cell Biol; 1991 Feb; 11(2):833-42. PubMed ID: 1671296
[TBL] [Abstract][Full Text] [Related]
2. The role of autophosphorylation in modulation of erbB-2 transforming function.
Segatto O; Lonardo F; Pierce JH; Bottaro DP; Di Fiore PP
New Biol; 1990 Feb; 2(2):187-95. PubMed ID: 1982072
[TBL] [Abstract][Full Text] [Related]
3. Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product.
Mikami Y; Davis JG; Dobashi K; Dougall WC; Myers JN; Brown VI; Greene MI
Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7335-9. PubMed ID: 1354355
[TBL] [Abstract][Full Text] [Related]
4. Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential.
Shu HK; Pelley RJ; Kung HJ
Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9103-7. PubMed ID: 1979168
[TBL] [Abstract][Full Text] [Related]
5. Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases.
Guy PM; Carraway KL; Cerione RA
J Biol Chem; 1992 Jul; 267(20):13851-6. PubMed ID: 1352772
[TBL] [Abstract][Full Text] [Related]
6. Structural elements that regulate pp59c-fyn catalytic activity, transforming potential, and ability to associate with polyomavirus middle-T antigen.
Cheng SH; Espino PC; Marshall J; Harvey R; Merrill J; Smith AE
J Virol; 1991 Jan; 65(1):170-9. PubMed ID: 1985196
[TBL] [Abstract][Full Text] [Related]
7. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma.
Borrello MG; Alberti L; Arighi E; Bongarzone I; Battistini C; Bardelli A; Pasini B; Piutti C; Rizzetti MG; Mondellini P; Radice MT; Pierotti MA
Mol Cell Biol; 1996 May; 16(5):2151-63. PubMed ID: 8628282
[TBL] [Abstract][Full Text] [Related]
8. Protein tyrosine kinase activities of the epidermal growth factor receptor and ErbB proteins: correlation of oncogenic activation with altered kinetics.
Nair N; Davis RJ; Robinson HL
Mol Cell Biol; 1992 May; 12(5):2010-6. PubMed ID: 1314948
[TBL] [Abstract][Full Text] [Related]
9. The multiple endocrine neoplasia type 2B point mutation alters long-term regulation and enhances the transforming capacity of the epidermal growth factor receptor.
Pandit SD; Donis-Keller H; Iwamoto T; Tomich JM; Pike LJ
J Biol Chem; 1996 Mar; 271(10):5850-8. PubMed ID: 8621456
[TBL] [Abstract][Full Text] [Related]
10. Disease tropism of c-erbB: effects of carboxyl-terminal tyrosine and internal mutations on tissue-specific transformation.
Pelley RJ; Maihle NJ; Boerkoel C; Shu HK; Carter TH; Moscovici C; Kung HJ
Proc Natl Acad Sci U S A; 1989 Sep; 86(18):7164-8. PubMed ID: 2550929
[TBL] [Abstract][Full Text] [Related]
11. NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant.
Messerle K; Schlegel J; Hynes NE; Groner B
Mol Cell Endocrinol; 1994 Oct; 105(1):1-10. PubMed ID: 7821711
[TBL] [Abstract][Full Text] [Related]
12. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway.
Ben-Levy R; Paterson HF; Marshall CJ; Yarden Y
EMBO J; 1994 Jul; 13(14):3302-11. PubMed ID: 7913890
[TBL] [Abstract][Full Text] [Related]
13. The amino-terminal region of pp60c-src has a modulatory role and contains multiple sites of tyrosine phosphorylation.
Espino PC; Harvey R; Schweickhardt RL; White GA; Smith AE; Cheng SH
Oncogene; 1990 Mar; 5(3):283-93. PubMed ID: 1690377
[TBL] [Abstract][Full Text] [Related]
14. A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation.
Lehväslaiho H; Lehtola L; Sistonen L; Alitalo K
EMBO J; 1989 Jan; 8(1):159-66. PubMed ID: 2565807
[TBL] [Abstract][Full Text] [Related]
15. The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity.
Di Fiore PP; Segatto O; Lonardo F; Fazioli F; Pierce JH; Aaronson SA
Mol Cell Biol; 1990 Jun; 10(6):2749-56. PubMed ID: 2188097
[TBL] [Abstract][Full Text] [Related]
16. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
Rodrigues GA; Park M
Oncogene; 1994 Jul; 9(7):2019-27. PubMed ID: 8208547
[TBL] [Abstract][Full Text] [Related]
17. A minor tyrosine phosphorylation site located within the CAIN domain plays a critical role in regulating tissue-specific transformation by erbB kinase.
Chang CM; Shu HK; Ravi L; Pelley RJ; Shu H; Kung HJ
J Virol; 1995 Feb; 69(2):1172-80. PubMed ID: 7815495
[TBL] [Abstract][Full Text] [Related]
18. Dissecting the activating mutations in v-erbB of avian erythroblastosis virus strain R.
Shu HK; Pelley RJ; Kung HJ
J Virol; 1991 Nov; 65(11):6173-80. PubMed ID: 1681117
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase activity may be necessary but is not sufficient for c-erbB1-mediated tissue-specific tumorigenicity.
Connolly DC; Toutenhoofd SL; Maihle NJ
J Virol; 1994 Oct; 68(10):6804-10. PubMed ID: 7916062
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the human c-fes protein tyrosine kinase (p93c-fes) by its src homology 2 domain and major autophosphorylation site (Tyr-713).
Hjermstad SJ; Peters KL; Briggs SD; Glazer RI; Smithgall TE
Oncogene; 1993 Aug; 8(8):2283-92. PubMed ID: 7687763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
